Streetbeat News

Regulatory

HIMS

LLY

NVO

Hims & Hers Health Inc (NYSE:HIMS) shares are falling due to the FDA's removal of Eli Lilly's (NYSE:LLY) diabetes and weight-loss drugs from the shortage list. This impacts Hims & Hers, which sells compounded versions of these drugs. Eli Lilly's improved supply may reduce demand for compounded alternatives.

Portfolio Pulse from Adam Eckert

October 03, 2024 | 1:31 pm

SPY

US weekly jobless claims rose to 225,000, slightly above expectations, indicating a cooling labor market. This may provide the Federal Reserve with room for potential easing measures.

Portfolio Pulse from Vandana Singh

October 03, 2024 | 1:17 pm

ZM

Zoom Video Communications, Inc. (NASDAQ:ZM) has launched its Zoom Phone service in India, starting with native phone numbers in the Maharashtra Telecom Circle. This expansion aims to provide multinational and local companies with modern communication solutions, covering major tech centers in India.

Portfolio Pulse from Benzinga Newsdesk

October 03, 2024 | 1:08 pm

AIM

AIM ImmunoTech has been granted U.S. Patent No. 12,102,649 for its drug Ampligen, which is intended for the treatment of endometriosis. This patent could potentially enhance AIM ImmunoTech's market position and future revenue streams.

Portfolio Pulse from Benzinga Newsdesk

October 03, 2024 | 12:46 pm

EVGO

EVgo Inc. has received a conditional commitment for a $1.05 billion loan guarantee from the U.S. Department of Energy to expand its fast charging network across the U.S. This financing will support the construction of approximately 7,500 new DC fast charging stalls.

Portfolio Pulse from Benzinga Newsdesk

October 03, 2024 | 12:41 pm

GRRR

Gorilla Technology Group Inc. (NASDAQ:GRRR) is actively combating market manipulation of its stock and plans to repurchase more shares under its buyback program, indicating confidence in its undervalued stock.

Portfolio Pulse from Benzinga Newsdesk

October 03, 2024 | 12:21 pm

PCRX

Pacira BioSciences announced that the Centers for Medicare and Medicaid Services has issued a new J-code for EXPAREL, effective January 1, 2025. This change is expected to streamline billing and reimbursement processes.

Portfolio Pulse from Benzinga Newsdesk

October 03, 2024 | 12:12 pm

BABA

JD

NIO

XPEV

US-listed Chinese stocks are experiencing a decline after a recent rally spurred by a new stimulus package from the People's Bank of China. The pullback comes as the sector adjusts following the initial boost.

Portfolio Pulse from Benzinga Newsdesk

October 03, 2024 | 12:06 pm

IMMP

Immutep Limited has completed patient enrollment for the Phase II AIPAC-003 trial, testing eftilagimod alpha with paclitaxel in metastatic breast cancer patients. The trial aims to determine the optimal biological dose, aligning with FDA's Project Optimus.

Portfolio Pulse from Benzinga Newsdesk

October 03, 2024 | 12:04 pm

OSTX

OS Therapies has completed a Phase 2b clinical trial for OST-HER2 in recurred osteosarcoma and is preparing to request an FDA Type C meeting. The company expects data analysis and topline results in Q4 2024. OS Therapies will ring the NYSE closing bell today, and CEO Paul Romness will appear on Fintech.TV and Schwab Network.

Portfolio Pulse from Benzinga Newsdesk

October 03, 2024 | 12:03 pm